Avtor/Urednik		Norman, J; Thong, KJ; Gomez, M; Pretnar-Darovec, A; Reš, P; Kovacz, L; Nemeth, G; et, al
Naslov		Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial
Tip		članek
Vir		Hum Reprod
Vol. in št.		Letnik 10, št. 2
Leto izdaje		1995
Obseg		str. 308-14
Jezik		eng
Abstrakt		A multicentre trial was conducted to evaluate whether a combination regimen of a 600 mg dose of the antiprogestogen, mifepristone, followed 48 h later a 1 mg vaginal suppository of the prostaglandin analogue, gemeprost, could be an effective pharmacological method for menstrual regulation. A total of 228 women with menstrual delay of less th. 11 days were studied in nine centres; 35 of the women (15 percent) received the treatment without having been pregnant as determined by human chorionic gonadotrophin measurements performed retrospectively. The mifepristone-gemeprost regimen induced vaginal bleeding in all of the pregnant women and in all but two of the non-pregnant women, and a complete abortion in all but four of the 193 pregnant subjects. The four failures included one incomplete and two missed abortions and one continuing live pregnancy. Most women reported lower abdominal pain during the first few hours after gemeprost administration but few, if any, other side-effects were observed. Most non-pegnant women described the induced vaginal bleeding to be comparable with - albeit somewhat longer than - a normal menstruation. In pregnant women the duration of the bleeding was on average longer, and the amount greater, than normal menstruation, but haemoglobin concentrations in these women as well as in the nonpregnant subjects were not affected. The overall success rate (97.4 percent; 95 percent confidence interval: 94.4-99.4-99.0 percent) of th regimen employed in this pilot trial strongly suggests that the combination of an antiprogestogen followed by a suitable pros taglandinis potentialy useful for menstrual regulation and probably also as a late luteal, once-a-month contraceptive. Furher research is needed to optimize this regimen and assess its practical value and acceptability.
Deskriptorji		MENSTRUAL CYCLE MENSTRUATION DISORDERS MIFEPRISTONE ABORTION, INDUCED ALPROSTADIL TREATMENT OUTCOME WORLD HEALTH ORGANIZATION PROSTAGLANDINS E, SYNTHETIC DRUG THERAPY, COMBINATION HEMOGLOBINS